| Delaware         (State of incorporation)                                                                                                                                                                                                                                                                                                         | 36-3463683(I.R.S. employer identification no.) |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
|                 99 West Street, Suite J                  Medfield, Massachusetts                 (Address of principal executive offices) |  02052(Zip Code)                          |

| Large accelerated filer  | Accelerated filer   |
|----------------------------------|-----------------------------|
| Non-accelerated filer    | Smaller reporting company x |

----

----

----

----

----

----

| Listing of United States Patents |
|----------------------------------|
|                             |   |   |
| Patent Number                    |              Title |  Issue Date |
| 5,227,161                        | “Method to Clean and Disinfect Pathogens on the Epidermis by Applying a Composition Containing Peroxidase, Iodide Compound and Surfactant” | July 13, 1993   |
| 5,370,815                        | “Viscous Epidermal Cleaner and Disinfectant” | December 6, 1994  |
| 5,389,385                        | “Treatment of Iodine Deficiency Diseases” | February 14, 1995  |
| 5,589,198                        | “Treatment of Iodine Deficiency Diseases” | December 31, 1996  |
| 5,885,592                        | “Method & Pharmaceutical Compositions for Oral Administration of Molecular Iodine” | March 23, 1999   |
| 5,910,318                        | “Treatment of Iodine Deficiency Diseases” | June 8, 1999  |
| 5,955,101                        | “Dry Starch-Iodine Pharmaceutical Formulations” | September 21, 1999  |
| 5,962,029                        | “Iodine Germicides that Continuously Generate Free Molecular Iodine”  | November 5, 1999 |
| 6,019,970                        | “Treatment of Iodine Deficiency Diseases” | February 1, 2000  |
| Re 36,605                        | “Reissue of 08/963,900 Method to Clean and Disinfect Pathogens”  | March 7, 2000 |
| 6,248,335                        | “Stabilized Oral Pharmaceutical Composition Containing Iodide and Iodate”  | June 19, 2001 |
| 6,432,426                        | “Non-Staining Topical Iodine Composition and Method” | August 13, 2002 |

----

| Name                   | Age    | Position with the Company           |
|------------------------|--------|-------------------------------------|
|                   |   |                                |
| Paul C. Desjourdy      | 49     | President, Chief Executive Officer, |
|                   |   | Chief Financial Officer, General    |
|                   |   | Counsel, Treasurer and Director     |
|                   |   |                                |
| Jack H. Kessler, Ph.D. | 60     | Chaiman of the Board and Secretary  |

----

----

| ·   | conducting preclinical and clinical trials; |
|--------------------|---------------------------------------------|

| ·   | obtaining required regulatory approvals of drug candidates; |
|--------------------|-------------------------------------------------------------|

| ·   | manufacturing any resulting products; and |
|--------------------|-------------------------------------------|

| ·   | commercializing any resulting products. |
|--------------------|-----------------------------------------|

----

----

----

----

|           | Fiscal 2010                   |                          | Fiscal 2009 |
|----------------|-------------------------------|-------------------------------|-------------|
|           | High                          | Low                           |        | High | Low |
|           |                          |                          |        |   |   |
| First quarter  | $    0.27 | $    0.09 |        | $   0.01 | $    0.01 |
| Second quarter | 0.11                          |    0.03        |        | 0.05 |    0.01 |
| Third quarter  | 0.04                          |    0.02        |        | 0.07 |    0.01 |
| Fourth quarter | 0.03                          |    0.01        |        | 0.17 |    0.03 |

----

----

----

----

----

----

----

|                                                        |   |         |
|-------------------------------------------------------------|--------|--------------|
|                                                        |   | December 31, |
|                                                        |   |         | 2010 |   |   | 2009 |   |
|                                                        |   |         |   |   |   |   |   |
| Assets                                                      |   |         |   |   |   |   |   |
|                                                        |   |         |   |   |   |   |   |
| Current assets:                                             |   |         |   |   |   |   |   |
|    Cash and cash equivalents                 |   | $            | 28,116 |   | $ | 14,712 |   |
|    Accounts receivable                            |   |         | 765 |   |   | -  |   |
|    Prepaid insurance                              |   |         | 164,335 |   |   | - |   |
| Other prepaid expenses                                      |   |         | 869 |   |   | 1,375 |   |
|                                                        |   |         |   |   |   |   |   |
|     Total current assets                     |   |         | 194,085 |   |   | 16,087 |   |
|                                                        |   |         |   |   |   |   |   |
| Property and equipment, net                                 |   |         | 74 |   |   | 624  |   |
|                                                        |   |         |   |   |   |   |   |
| Other assets:                                               |   |         |   |   |   |   |   |
|     Equity Investments (Notes 2 and 10) |   |         | (20,000 | ) |   | -  |   |
| Intangible assets, net                                      |   |         | 3,068 |   |   | 4,299  |   |
|                                                        |   |         |   |   |   |   |   |
|  Total assets                                          |   | $            | 177,227 |   | $ | 21,010 |   |

----

|                                                                       |   |         |          |    |   |          |    |
|----------------------------------------------------------------------------|--------|--------------|---------------|---------|--------|---------------|---------|
|                                                                       |   | December 31, |
|                                                                       |   |         | 2010          |    |   | 2009          |    |
|                                                                       |   |         |          |    |   |          |    |
|  Liabilities and Stockholders’ Deficit                     |   |         |          |
|                                                                       |   |         |          |    |   |          |    |
| Current liabilities:                                                       |   |         |          |    |   |          |    |
| Accounts payable                                                           |   | $            | 107,923       |    | $      | 96,400        |    |
|     Accrued clinical development expenses                   |   |         |  112,763 |    |   |  112,763 |    |
|     Accrued officer salary                             |   |         | 270,000       |    |   |  108,000 |    |
| Deferred licensing revenues                                                |   |         | 130,202       |    |   | -             |    |
| Other payables                                                             |   |         | 6,516         |    |   | 38,522        |    |
|                                                                       |   |         |          |    |   |          |    |
|     Total current liabilities                               |   |         | 627,404       |    |   | 355,685       |    |
|                                                                       |   |         |          |    |   |          |    |
| Commitments (Notes 6, 7 and 9)                                             |   |         |          |    |   |          |    |
|                                                                       |   |         |          |    |   |          |    |
| Stockholders’ deficit:                                          |   |         |          |    |   |          |    |
| Common stock, Class A, par value $.001 per share, 93,750,000 shares        |   |         |          |    |   |          |    |
|   authorized, 42,656,673 and 28,723,340 shares issued and outstanding |   |         |          |    |   |          |    |
|   as of December 31, 2010 and 2009, respectively                      |   |         | 42,657        |    |   | 28,723        |    |
| Convertible common stock, Class B, par value $.001                         |   |         |          |    |   |          |    |
|   per share, 1,250,000 shares authorized and unissued                 |   |         | -             |    |   | -             |    |
| Preferred stock, par value $.001 per share, 5,000,000 shares               |   |         |          |    |   |          |    |
|   authorized and unissued                                             |   |         | -             |    |   | -             |    |
| Additional paid-in capital                                                 |   |         | 22,038,828    |    |   | 21,720,085    |    |
| Accumulated deficit                                                        |   |         | (22,531,662   | )       |   | (22,083,483   | )       |
|                                                                       |   |         |          |    |   |          |    |
|     Total stockholders' deficit                        |   |         | (450,177      | )  |   | (334,675      | )  |
|                                                                       |   |         |          |    |   |          |    |
|  Total liabilities and stockholders' deficit                          |   | $            | 177,227       |    | $      | 21,010        |    |

----

|                                                                    |   |   |                   |   |   |           |    |
|-------------------------------------------------------------------------|--------|--------|------------------------|--------|--------|----------------|---------|
|                                                                    |   |   | Year EndedDecember 31, |   |
|                                                                    |   |   | 2010                   |   |   | 2009           |    |
|                                                                    |   |   |                   |   |   |           |    |
| Revenue                                                                 |   | $      | 23,111                 |   | $      | 2,582          |    |
| Cost of goods sold                                                      |   |   |  6,788            |   |   |  1,485    |    |
|                                                                    |   |   |                   |   |   |           |    |
| Gross profit                                                            |   |   |  16,323           |   |   |  1,097    |    |
|                                                                    |   |   |                   |   |   |           |    |
| Operating expenses:                                                     |   |   |                   |   |   |           |    |
| Research and development                                                |   |   | -                      |   |   | 29,955         |    |
| Sales and marketing                                                     |   |   | 8,822                  |   |   | 2,018          |    |
| General and administrative                                              |   |   | 435,224                |   |   | 504,937        |    |
|                                                                    |   |   |                   |   |   |           |    |
|   Total operating expenses                                         |   |   | 444,046                |   |   | 536,910        |    |
|                                                                    |   |   |                   |   |   |           |    |
| Loss from operations                                                    |   |   | (427,723               | )      |   | (535,813       | )       |
|                                                                    |   |   |                   |   |   |           |    |
| Interest and other income (expense)                                     |   |   |                   |   |   |           |    |
|    Interest income                                       |   |   | -                      |   |   | 86             |    |
|    Loss on equity investment                             |   |   |  (20,000          | )      |   |  -        |    |
|    Other income (expense)                                |   |   | -                      |   |   |  (156,189 | )  |
|                                                                    |   |   |                   |   |   |           |    |
|      Total interest and other income (expense) |   |   | (20,000                | )      |   | (156,103       | )  |
|                                                                    |   |   |                   |   |   |           |    |
| Loss before income taxes                                                |   |   | (447,723               | )      |   | (691,916       | )  |
|                                                                    |   |   |                   |   |   |           |    |
| Provision for income taxes                                              |   |   | 456                    |   |   |  456      |    |
|                                                                    |   |   |                   |   |   |           |    |
| Net loss                                                                |   | $      | (448,179               | )      | $      | (692,372       | )       |
|                                                                    |   |   |                   |   |   |           |    |
| Net loss per share of common stock:                                |   |   |                   |   |   |           |    |
|   Basic                                                            |   | $      | (0.01                  | )      | $      | (0.03          | )       |
|                                                                    |   |   |                   |   |   |           |    |
| Weighted average shares outstanding                                     |   |   | 35,668,550             |   |   | 22,106,217     |    |

----

|                                                                 |   |   | Common Stock     |   |   |        |   |   |         |   |   |        |   |   |   |   |
|----------------------------------------------------------------------|--------|--------|-----------------------|--------|--------|-------------|--------|--------|--------------|--------|--------|-------------|--------|--------|--------|--------|
|                                                                 |   |   | $.001 Par Value  |   |   | Additional  |   |   |         |   |   |        |   |   |   |   |
|                                                                 |   |   | Class A          |   |   | Paid-in     |   |   | Accumulated  |   |   |        |   |   |   |   |
|                                                                 |   |   | Shares           |   |   | Amount      |   |   | Capital      |   |   | Deficit     |   |   |   |   |   | Total |   |
|                                                                 |   |   |                  |   |   |        |   |   |         |   |   |        |   |   |   |   |   |   |   |
| Beginning Balance on December 31, 2008                               |   |   | 16,473,340            |   | $      | 16,473      |   | $      | 21,526,658   |   | $      | (21,391,111 | )      |   |   |   | $ | 152,020 |   |
|     Issuance of shares – Executive stock grant  |   |   | 10,000,000            |   |   | 10,000      |   |   | 90,000       |   |   | -           |   |   |   |   |   | 100,000 |   |
|     Issuance of shares – Consultants            |   |   | 1,000,000             |   |   | 1,000       |   |   | 9,000        |   |   | -           |   |   |   |   |   | 10,000 |   |
|     Issuance of shares – Private placement      |   |   |  1,250,000       |   |   |  1,250 |   |   |  23,750 |   |   |        |   |   |   |   |   | 25,000 |   |
|     Stock based compensation                          |   |   | -                     |   |   | -           |   |   | 70,677       |   |   | -           |   |   |   |   |   | 70,677 |   |
|     Net loss, year ended December 31, 2009       |   |   | -                     |   |   | -           |   |   | -            |   |   | (692,372    | )      |   |   |   |   | (692,372 | ) |
|                                                                 |   |   |                  |   |   |        |   |   |         |   |   |        |   |   |   |   |   |   |   |
| Ending Balance on December 31, 2009                                  |   |   | 28,723,340            |   |   | 28,723      |   | $      | 21,720,085   |   | $      | (22,083,483 | )      |   |   |   | $ | (334,675 | )  |
|                                                                 |   |   |                  |   |   |        |   |   |         |   |   |        |   |   |   |   |   |   |   |
|     Issuance of shares – Board stock grant |   |   | 3,500,000             |   |   | 3,500       |   |   | -            |   |   | -           |   |   |   |   |   | 3,500 |   |
|     Issuance of shares – Consultants            |   |   | 1,700,000             |   |   | 1,700       |   |   | 39,500       |   |   | -           |   |   |   |   |   | 41,200 |   |
|     Issuance of shares – Private placement      |   |   | 8,733,333             |   |   | 8,734       |   |   | 233,267      |   |   | -           |   |   |   |   |   | 242,001 |   |
|     Stock based compensation                          |   |   | -                     |   |   | -           |   |   | 45,976       |   |   | -           |   |   |   |   |   | 45,976 |   |
|     Net loss, year ended December 31, 2010       |   |   | -                     |   |   | -           |   |   | -            |   |   | (448,179    | )      |   |   |   |   | (448,179 | ) |
|                                                                 |   |   |                  |   |   |        |   |   |         |   |   |        |   |   |   |   |   |   |   |
| Ending Balance on December 31, 2010                                  |   |   | 42,656,673            |   | $      | 42,657      |   | $      | 22,038,828   |   | $      | (22,531,662 | )      |   |   |   | $ | (450,177 | )  |

----

|                                                                                                                                             |   |     |                   |    |     |     |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|------------------------|---------|----------|----------|--------|
|                                                                                                                                             |   |     | Year EndedDecember 31, |    |
|                                                                                                                                             |   |     | 2010                   |    |     | 2009     |   |
| Cash flows from operating activities:                                                                                                            |   |     |                   |    |     |     |   |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Net loss                                                                                                                                         |   | $        | (448,179               | )       | $        | (692,372 | )      |
| Adjustments to reconcile net income (loss) to net cash used in                                                                                   |   |     |                   |    |     |     |   |
|   operating activities:                                                                                                                     |   |     |                   |    |     |     |   |
|         Depreciation and amortization                                                                         |   |     | 1,433                  |    |     | 24,583   |   |
|     Stock-based compensation expense                                                                                              |   |     | 45,976                 |    |     | 128,416  |   |
|     Issuance of securities for services rendered                                                                                  |   |     | 44,701                 |    |     | 52,261   |   |
|     Loss on equity investments                                                                                                    |   |     | 20,000                 |    |     | -        |   |
|         Loss on impairment of patents and trademarks                                                          |   |     | 347                    |    |     | 178,337  |   |
|         Loss of rental deposit                                                                                |   |     | -                      |    |     | 2,364    |   |
|     Changes in operating assets and liabilities:                                                                                  |   |     |                   |    |     |     |   |
|       Inventory                                                                                                         |   |     | -                      |    |     | 30,085   |   |
|           Accounts receivable                                                                  |   |     |  (765             | )       |     |  -  |   |
|       Prepaid expenses                                                                                                  |   |     | (163,829               | )  |     | 19,888   |   |
|       Accounts payable and other current liabilities                                                                    |   |     | 271,719                |    |     | 179,908  |   |
| Net cash used in operating activities                                                                                                            |   |     | (228,596               | )       |     | (76,530  | )      |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Cash flows from financing activities:                                                                                                            |   |     |                   |    |     |     |   |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Proceeds from issuance of common stock and warrants                                                                                              |   |     | 242,000                |    |     | 25,000   |   |
| Net cash provided by financing activities                                                                                                        |   |     | 242,000                |    |     | 25,000   |   |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Net change in cash                                                                                                                     |   |     | 13,404                 |    |     | (51,530  | )      |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Cash and cash equivalents at beginning of period                                                                                                 |   |     | 14,712                 |    |     | 66,242   |   |
|                                                                                                                                             |   |     |                   |    |     |     |   |
| Cash and cash equivalents at end of period                                                                                                       |   | $        | 28,116                 |    | $        | 14,712   |   |
|  Supplemental disclosure of non-cash investing and financingactivities:    Issuance of securities for services rendered |   |   $ | -                      |    |   $ | -   |   |
|  Supplemental disclosure of cash flow information:                                                                 |   |   $ | -                      |    |   $ | -   |   |
|     Cash paid for taxes                                                                                       |   |   $ | -                      |    |   $ | -   |   |

----

| 1.         Description ofBusiness andBasis ofPresentation | Symbollon Pharmaceuticals, Inc. (formerly Symbollon Corporation) was formed to develop and commercialize proprietary iodine-based products for infection control and treatment in biomedical and bioagricultural industries. The success of future operations is subject to a number of risks similar to those of other companies in the same stage of development.  Principal among these risks are the Company’s cumulative operating losses, no assurance of profitable future operations, early state of market development, competition from substitute products or larger companies, dependence on key personnel and the uncertainty of additional future financing as needed. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the company as a going concern.  The Company had net losses of $448,179 and $692,372 and negative cash flows from operations of $228,596 and $76,530 for the years ended December 31, 2010 and 2009, respectively.  At December 31, 2010, the Company had an accumulated deficit of $22,531,662 and negative working capital of $433,319.  The Company does not have adequate cash resources to continue our base operations.  These factors raise substantial doubt about the company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize the Company’s assets and discharge our liabilities in other than the normal course of operations. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to receive continued financial support from the Company’s creditors, stockholders and external investors and to increase sales of Iogen, the Company’s dietary supplement marketed to promote breast health for women.  Management is actively seeking equity and debt financing from external investors, and is attempting to increase sales of Iogen.  The Company is also pursuing other strategic options, including possible sales or licenses of its technology or a sale or merger of the Company.  In December 2008, the Company transferred certain intellectual property in exchange for an equity stake in BioCide Pharma, Inc., a start-up company, and the assumption of approximately $18,000 in debt (see footnote 10 below).  In 2010, the Company raised $242,000 in private placements of 8,733,333 shares of common stock and warrants to purchase 666,666 shares of common stock.  Failure to either obtain the support of additional external investors to finance the Company’s operations, increase sales of Iogen or execute the Company’s other strategic options will cause us to cease operations in the near future.   |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.         Summary ofSignificantAccounting Policies  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Use of Estimates                                                                                       | The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Cash and CashEquivalents                                                                          | Cash and cash equivalents include short-term, highly liquid investments with maturities of less than three months when acquired.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Concentration ofCredit Risks                                                                           | In 2008, the Company launched Iogen as a dietary supplement for the promotion of female breast health.  Currently, the Company is selling Iogen through its website, www.BuyIogen.com, and retail outlets.  Online purchases of Iogen are made through credit card transactions, and certain retailers are granted credit terms or sell on consignment.  The Company had accounts receivable outstanding of $765 and none as of December 31, 2010 or 2009, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Long-Lived Assets                                                                                      | Long-lived assets, such as intangible assets and property and equipment are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows from the use of these assets.  When any such impairment exists, the related assets are written down to fair value.  In 2010 and 2009, the Company performed an evaluation based on changes in events and circumstances related to the Company’s ability to generate sufficient projected future cash flows to cover the capitalized costs of certain patents.  Based on the evaluation, the Company wrote off $347 and $178,337, respectively, of impaired trademark and patent costs.  The Company does not believe that any of its other long-lived assets are impaired at December 31, 2010 or 2009.  |
| Depreciation andAmortization                                                                           | Equipment is stated at cost and is depreciated over its estimated useful life (ranging from 5-7 years) using the straight-line method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

----

| 2.         Summary ofSignificantAccounting Policies(Continued)  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intangible Assets                                                                                                 | Intangible assets subject to amortization consist of patents that have estimated useful lives ranging from 9-17 years and a weighted average remaining useful life of 4.2 years.  Costs related to patent applications are capitalized as incurred and are amortized once the patent application is accepted or are expensed if the application is rejected or there are other circumstances that indicate that the asset is impaired (as described above).                                                                                                                                            |
| Income Taxes                                                                                                      | The Company follows the liability method of accounting for income taxes.  Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amount and the tax basis of assets and liabilities.  The Company records a valuation allowance against deferred tax assets unless it is more likely than not that such asset will be realized in future periods.                                                                                                                                      |
| Fair value ofFinancialInstruments                                                                            | The carrying amounts of cash and cash equivalents, other current assets and accounts payable approximate fair value based on their short-term maturities.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| EquityInvestment                                                                                                  | On December 8, 2008, the Company acquired 625,000 shares of common stock in BioCide Pharma, Inc., a start-up venture, in exchange for a transfer of certain patent rights and assumption of liabilities.  The Company accounts for this investment using the equity method according to ASC 323, “Investment—Equity Method and Joint Ventures.”  During the year ended December 31, 2010, the Company recorded a $20,000 loss on this investment.  At December 31, 2010 and 2009, the Company’s investment had value of $(20,000) and none, respectively.  |
| RevenueRecognition                                                                                                | The Company recognizes revenue from its product sales and licensing arrangements in accordance with SEC guidelines.  Under these guidelines, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services rendered, the price is fixed or determinable and payment is reasonably assured.  Licensing revenues are recognized over the term of licensing period.                                                                                                                                                                                     |

----

| 2.         Summary ofSignificantAccounting Policies(Continued)  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Deferred LicensingRevenues                                                                                   | On October 8, 2010, the Company entered into a Technology License Agreement with Organic Business Alliances, LLC and KSIA, LLC.  Pursuant to the agreement, the Company granted a non-exclusive license to KSIA to develop products based on its technology.  To the extent any products are developed under the license, Symbollon has a right to manufacture and sell such products to KSIA for resale.  Symbollon also granted KSIA a non-exclusive license to purchase Iogen for 50% off the suggested retail price for resale.  Pursuant to the agreement, OBA agreed to fund key-man life insurance cost for the officers and directors of Symbollon up to $3,750,000.  Under the agreement, Symbollon received $144,668 in licensing payments which was used to purchase key-man life insurance.  The Company recognized $14,467 of licensing revenue for the year ended December 31, 2010 and a like amount of key-man insurance premium expenses.  At December 31, 2010, the remaining $130,202 was recorded as deferred licensing revenue and will be recognized as revenue in 2011 over the remaining license period.  |
| Advertising Costs                                                                                                 | Advertising costs are charged to operations when incurred.  In the years ended December 31, 2010 and 2009 the Company incurred $7,361 and $1,868, respectively, in advertising costs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Research andDevelopment                                                                                      | Research and development costs are expensed as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Stock-BasedCompensation                                                                                      | The Company accounts for share-based compensation based on the option’s fair value and the vesting period of the award.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Loss Per Share                                                                                                    | Basic earnings per share excludes the effect of any dilutive options, warrants or convertible securities and is computed by dividing the net earnings available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted earnings per share is computed by dividing the net earnings available to common shareholders by the sum of the weighted average number of common shares and common share equivalents computed using the average market price for the period under the treasury stock method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adoption of WarrantAccounting                                                                                | In June 2008, FASB issued guidance (now ASC 718, “Stock Compensation”) for determining whether an equity-linked financial instrument (or embedded feature) is indexed to an entity’s own stock. This guidance applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative. This guidance is effective for fiscal years beginning after December 15, 2008.  We have concluded that adoption of this guidance on January 1, 2009 did not have a material impact on the Company’s financial statements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

|     Recent Accounting     Pronouncements  | In April 2009, the FASB issued an update to ASC 820, “Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly”, which provides guidance on determining fair value when there is no active market or where the price inputs being used represent distressed sales.  This update to ASC 820 was effective for interim and annual periods ending after June 15, 2009 and was adopted by the Company in the second quarter of 2009.  The adoption did not have a material impact on the Company’s financial statements. In May 2009, the FASB issued ASC 855, “Subsequent Events”.  ASC 855 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued.  ASC 855, which includes a new required disclosure of the date through which an entity has evaluated subsequent events, was effective for interim or annual periods ending after June 15, 2009.  The Company adopted this standard as of June 30, 2009; however, the adoption of ASC 855 had no impact to the Company’s financial statements.In June 2009, the FASB issued ASU 2009-17, Consolidation (ASC 810) “Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities,” which eliminates the quantitative approach previously required for determining the primary beneficiary of a variable interest entity and requires ongoing qualitative reassessments of whether an enterprise is the primary beneficiary of a variable interest entity.  This new standard also requires additional disclosures about an enterprise’s involvement in variable interest entities. The Company adopted this pronouncement on January 1, 2010 but there was no significant impact on its financial statements. In June 2009, the FASB issued ASC 105, “The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles”.  ASC 105 establishes the FASB Accounting Standards Codification (“Codification”), as the single source of authoritative accounting and reporting standards in the United States for all non-government entities, with the exception of the Securities and Exchange Commission and its staff.  It does not include any new guidance or interpretations of US GAAP, but merely eliminates the existing hierarchy and codifies the previously issued standards and pronouncements into specific topic areas.  The Codification was adopted on July 1, 2009 for the Company’s financial statements for the year ended December 31, 2009.  |
|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|     Recent Accounting     Pronouncements    (continued)  | In January 2010, the FASB issued ASU 2010-06, “Fair Value Measurements and Disclosures (ASC 820): Improving Disclosures about Fair Value Measurements.”  This update will require (1) an entity to disclose separately the amounts of significant transfers in and out of Levels 1 and 2 fair value measurements and to describe the reasons for the transfers; and (2) information about purchases, sales, issuances and settlements to be presented separately (i.e. present the activity on a gross basis rather than net) in the reconciliation for fair value measurements using significant unobservable inputs (Level 3 inputs).  This guidance clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and require disclosures about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs.  The new disclosures and clarifications of existing disclosure are effective for fiscal years beginning after December 15, 2009, except for the disclosure requirements for related to the purchases, sales, issuances and settlements in the roll forward activity of Level 3 fair value measurements.  Those disclosure requirements are effective for fiscal years ending after December 31, 2010.  The Company is still assessing the impact on this guidance and does not believe the adoption of this guidance will have a material impact to its financial statements.  Management does not believe that other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants or the SEC have a material impact on the Company’s present or future financial statements. In February 2010, the FASB issued guidance to remove the requirement for an entity that files financial statements with the SEC to disclose a date through which subsequent events have been evaluated.  The adoption of this guidance during our current fiscal quarter did not have any impact on our financial statements.  |
|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.         Equipment                                                              | Equipment is stated at cost and consist of the following:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

| December 31,                        | 2010                                                      | 2009                                     |
|-------------------------------------|-----------------------------------------------------------|------------------------------------------|
|                                |                                                      |                                     |
| Equipment                           | $   30,710                                 | $  30,710                      |
|                                |                                                      |                                     |
|                                |                                                      |                                     |
|                                | 30,710                                                    | 30,710                                   |
|                                |                                                      |                                     |
|  Less accumulated depreciation | 30,636                                                    | 30,086                                   |
|                                |                                                      |                                     |
| Equipment, net                      | $         74 | $      624 |

|   | Depreciation expense for the years ended December 31, 2010 and 2009 totaled $550 and $1,003, respectively.  |
|--------|------------------------------------------------------------------------------------------------------------------|

----

| 4.         Patent andTrademark Costs | Patent and trademark costs consist of the following:  |
|-----------------------------------------------------------------------------------|------------------------------------------------------------|

| December 31,                         | 2010                                                         | 2009                                       |
|--------------------------------------|--------------------------------------------------------------|--------------------------------------------|
|                                 |                                                         |                                       |
| Patent costs                         | $      10,872                  | $     10,872      |
| Trademark costs                      | -                                                            | 2,444                                      |
|                                 |  10,872                                                 |  13,316                               |
|  Less accumulated amortization  |  7,804                                                  |  9,017                                |
|  Patent and trademark cost, net |  $        3,068 |  $     4,299 |

|                                                                                                                                                                 | Amortization expense related to these assets is estimated to be approximately $725 per year in fiscal years 2011 through 2016.  Amortization expense for the years ended December 31, 2010 and 2009 totaled $884 and $23,580, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.         Stockholders’Equity                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Capital Stock                                                                                                                                                        | The Company has authorized 93,750,000 shares of Class A common stock, 1,250,000 shares of Class B common stock and 5,000,000 shares of preferred stock.  The Class A and Class B common stock are substantially identical except that holders of Class A common stock have the right to cast one vote for each share held and the Class B shareholders have the right to cast five votes for each share held.  As of December 31, 2010 and 2009, there were no shares of Class B common stock issued and outstanding.  The preferred stock may be issued in series, and shares of each series will have such rights and preferences as are fixed by the Company’s Board of Directors.  As of December 31, 2010 and 2009, there were no shares of preferred stock issued and outstanding.  |
| Issuance of CommonStock and Common         Stock Purchase         Warrants | The Company has recognized $44,701 and $52,261 of expense related to certain of the shares and warrants issued for services for the years ended December 31, 2010 and 2009, respectively, in the accompanying statements of operations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

----

| 5.         Stockholders’Equity(Continued)                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Issuance of CommonStock and Common         Stock Purchase         Warrants(Continued) | On June 29, 2009, the Company issued 10,000,000 shares to its executive officer, Mr. Desjourdy and 1,000,000 shares to certain consultants.  The Company recorded $110,000 of stock-based compensation for the year ended December 31, 2009 as general and administrative expenses. On December 24, 2009, the Company sold in a private placement to accredited investors an aggregate of 1,250,000 shares of Class A common stock for net proceeds of $25,000 in cash.  On January 11, 2010, the Company sold in a private placement to accredited investors an aggregate of 3,750,000 shares of Class A common stock for net proceeds of $75,000 in cash.  On March 31, 2010, the Company sold in a private placement to accredited investors an aggregate of 666,666 shares of Class A common stock, and warrants to purchase a like number of additional shares, for net proceeds of $50,000 in cash.  On June 30, 2010, the Company sold in a private placement to accredited investors an aggregate of 1,250,000 shares of Class A common stock for net proceeds of $25,000 in cash.  On October 8, 2010 and December 31, 2010, the Company sold in a private placement to an accredited investor an aggregate of 3,066,667 shares of Class A common stock for net proceeds of $92,000 in cash. On June 7, 2010 and September 16, 2010, the Company issued 1,700,000 shares of Class A common stock to certain consultants for $41,200 of services rendered.  The Company recorded these consulting costs for the year ended December 31, 2010 as general and administrative expenses. On September 16, 2010 and October 15, 2010, the Company issued 3,500,000 to its non-officer directors.  The Company recorded $12,502 of stock-based compensation for the year ended December 31, 2010 as general and administrative expenses. At December 31, 2009, warrants to purchase 7,960,398 shares of common stock are outstanding.  |

----

| 6.         Stock Plans  | The Company has adopted two stock plans:  a stock option plan and a nonemployee directors’ stock option plan. The stock option plan provides for the grant of incentive stock options, nonqualified stock options and stock appreciation rights.  The stock option plan expired on August 4, 2008 with options to purchase 1,225,000 shares outstanding at December 31, 2009.  No future grants may be made under this plan. On May 24, 2006 the Company adopted a 2006 nonemployee directors’ stock option plan that provides for the grant of nonstatutory stock options automatically on January 1 of each calendar year commencing on January 1, 2007.  The Company has reserved 500,000 shares for issuance under the plan.  Each outside director shall be granted an option to purchase 10,000 shares of Class A common stock at fair market value, vesting 50% on each of the first two anniversaries of the grant.  The nonemployee directors’ stock option plan expires on the first business day of 2017.  Under the plan 360,000 shares are available for future grant. Through December 31, 2008 the Company issued stock options to its employees and outside directors pursuant to stockholder-approved stock option plans.  On October 1, 2009 the Company issued stock options to its outside directors outside of a stockholder-approved stock option plan.  Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant.  Employee option awards generally vest over three years from the date of grant, and outside directors option awards generally vest over two years from the date of grant.  All option awards generally have 10-year contractual terms.  The Company attributes stock-based compensation cost to operations using the straight-line method over the applicable vesting period. The Company recorded $45,676 and $128,416 of stock-based compensation for the years ended December 31, 2010 and 2009, respectively, in general and administrative expenses.  As of December 31, 2010 the unrecognized stock-based compensation cost related to non-vested stock awards was $101,317.  This amount will be recognized in operations over a weighted average period of 18 months.  |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.         Stock Plans(Continued) | The following table summarizes the Company’s stock option information as of, and for the year ended December 31, 2010: |
|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                  |   Number ofShares |  WeightedAverageExercisePrice                    | Weighted AverageRemainingContractualTerm |   AggregateIntrinsicValue (1) |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------|------------------------------------------|-----------------------------------------|
|                                                                                                                                                                  |                        |                                                  |                                     |                                    |
| Outstanding at December 31, 2009                                                                                                                                      | 3,377,500                   | $       0.93       |                                     |                                    |
|    Options granted                                                                                                                                     |  40,000                |  $       0.15 |                                     |                                    |
|   Options expired                                                                                                                                           | (1,007,500)                 | $       0.90       |                                     |                                    |
|  Outstanding at December 31, 2010                                                                                                                                |  2,410,000             |  $       0.15 |  8.3                                |  $400,000                          |
|  Exercisable at December 31, 2010                                                                                                                                |  1,350,000             |  $       0.24 |  7.9                                |  $200,000                          |
|  (1)  The intrinsic value of a stock option is the amount by which the current market value of the underlying stock exceeds the option exercise price. |

|   | For the years ended December 31, 2010 and 2009, the Company granted options for 40,000 and 2,040,000 shares exercisable between $0.01 and $0.15 per share.  The weighted-average grant date fair value of stock options granted during the years ended December 31, 2010 and 2009 was $0.15 and $0.03 per share, respectively.  No stock options were exercised during the years ended December 31, 2010 or 2009.  |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:                                                                                                                                                                                                                                                                                       |

|                                                        |   | Year EndedDecember 31, |
|-------------------------------------------------------------|--------|------------------------|
|                                                        |   | 2010                   | 2009 |
|                                                        |   |                   |   |
| Weighted-average expected stock-price  volatility |   | 143%                   | 143-145% |
|                                                        |   |                   |   |
| Weighted-average expected option life                       |   | 6 years                | 6 years |
|                                                        |   |                   |   |
| Average risk-free interest rate                             |   | 2.65%                  | 1.72-2.20% |
|                                                        |   |                   |   |
| Average dividend yield                                      |   | 0.0%                   | 0.0% |

----

| 6.         Stock Plans(Continued) | The dividend yield of zero is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.  Expected volatility is based on the historical volatility of the Company’s common stock over the period commensurate with the expected life of the options.  The risk-free interest rate is the U.S. Treasury Strips rate on the date of grant.  The expected life was calculated using the 0.0% simplified method as the Company’s historical experience does not provide a reasonable basis for the expected term of the option.  Based on the recent history and current expectations, the Company has not adjusted the calculated value of the options for the year ended December 31, 2010 to reflect a forfeiture rate. |
|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | All options outstanding at December 31, 2010 are expected to vest and are categorized by the following ranges in the table below: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------|

|    SharePrice Range |  Weighted-AverageExercisePrice | Weighted-AverageRemainingContractualLife (years) |    Number ofShares |
|------------------------------------|-------------------------------------|--------------------------------------------------|-----------------------------------|
| $0.01 to $1.00                     | $0.09                               | 8.5                                              | 2,320,000                         |
| $1.00 to $1.93                     | $1.67                               | 2.9                                              | 90,000                            |
|                               |                                |                                             |  2,410,000                   |

|   | All options exercisable at December 31, 2010 are categorized by the following ranges in the table below: |
|--------|---------------------------------------------------------------------------------------------------------------|

|    SharePrice Range |  Weighted-AverageExercisePrice | Weighted-AverageRemainingContractualLife (years) |    Number ofShares |
|------------------------------------|-------------------------------------|--------------------------------------------------|-----------------------------------|
| $0.01 to $1.00                     | $0.14                               | 8.3                                              | 1,260,000                         |
| $1.00 to $1.93                     | $1.67                               | 2.9                                              | 90,000                            |
|                               |                                |                                             |  1,350,000                   |

|   | The weighted-average fair value of options granted during the years ended December 31, 2010 and 2009 was $0.15 and $0.03 per share, respectively.  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.         Loss Per Share | The Company’s basic and diluted net loss per share of common stock for the years ended December 31, 2010 and 2009 is computed by dividing the net loss by the weighted average number of common shares outstanding during the period.  |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                   | The following table summarizes securities that were outstanding as of December 31, 2010 and 2009 but not included in the calculation of diluted net loss per share because such shares are antidilutive:                                          |

| December 31,   | 2010      | 2009      |
|----------------|-----------|-----------|
|           |      |      |
| Stock options  | 2,410,000 | 3,377,500 |
| Stock warrants | 7,960,398 | 7,293,732 |

| 8.         Income Taxes | The following table summarizes the significant differences between the benefit that would be recognized under the United States federal statutory tax rate and the Company’s effective tax rate for financial statement purposes: |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| December 31,                                                    | 2010           | 2009           |
|-----------------------------------------------------------------|----------------|----------------|
|                                                            |           |           |
| United States federal statutory tax rate                        | 34%            | 34%            |
| State taxes, net of United States                               |           |           |
|    federal tax benefit                           | 6%             | 6%             |
|                                                            |           |           |
| Valuation allowance provided against net                        |           |           |
|    operating loss carry forwards and tax credits | (40%)          | (40%)          |
|                                                            |           |           |
| Effective tax rate                                              | -  % | -  % |

|   | Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations.  Deferred tax assets are comprised of the following: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| December 31,                     | 2010                                                                                                     | 2009                                                                                                     |
|----------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                             |                                                                                                     |                                                                                                     |
| Tax credit carryforwards         | $      607,000                                                             | $      653,000                                                             |
| Net operating loss carryforwards | 6,367,000                                                                                                | 6,830,000                                                                                                |
|                             |                                                                                                     |                                                                                                     |
| Gross deferred tax asset         | 6,974,000                                                                                                | 7,483,000                                                                                                |
|                             |                                                                                                     |                                                                                                     |
| Deferred tax assets valuation    |                                                                                                     |                                                                                                     |
|   allowance            | (6,974,000)                                                                                              | (7,483,000)                                                                                              |
|                             |                                                                                                     |                                                                                                     |
| Net deferred tax assets          | $                 - | $                 - |

----

| 8.         Income Taxes(Continued) | As of December 31, 2010 and 2009, the deferred tax assets have been fully offset by valuation allowances, since the realization of such amounts is uncertain.  The change in the valuation allowance during 2010 and 2009 was $509,000 and $470,000, respectively. As of December 31, 2010, the Company has net operating loss carryforwards totaling approximately $15,916,000.  The amount of the net operating loss carryforwards which may be utilized in any future period may be subject to certain limitations, based upon changes in the ownership of the Company’s common stock.  |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                            | The following is a breakdown of the net operating loss expiration period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|            | Amount of                |
|-----------------|----------------------------------------------|
| Expiration Date | Remaining NOL                                |
| 2011            | $      921,000 |
| 2018            | 897,000                                      |
| 2019            | 739,000                                      |
| 2020            | 476,000                                      |
| 2021            | 1,387,000                                    |
| 2022            | 612,000                                      |
| 2023            | 638,000                                      |
| 2024            | 2,061,000                                    |
| 2025            | 953,000                                      |
| 2026            | 2,319,000                                    |
| 2027            | 3,330,000                                    |
| 2028            | 840,000                                      |
| 2029            | 359,000                                      |
| 2030            | 384,000                                      |
|            | $ 15,916,000                                 |

|   | In addition, the Company has available tax credit carryforwards (adjusted to reflect provisions of the Tax Reform Act of 1986) of approximately $607,000, which are available to offset future taxable income and income tax liabilities, when earned or incurred.  These amounts expire in various years through 2030.  The amount of the tax credit carryforwards which may be utilized in any future period may be subject to certain limitations, based upon changes in the ownership of the Company’s common stock. The Company files income tax returns in the U.S. federal jurisdiction and in several state jurisdictions. For U.S. federal and state tax purposes, the tax years 2007 through 2010 remain open to examination.  In addition, the amount of the Company’s federal and state net operating loss carryforwards may be subject to examination and adjustment. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.         Commitments  |                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Facilities Lease                                                          | The Company leases its facilities on a month-to-month basis.  Rent expense for the years ended December 31, 2010 and 2009 was approximately $10,800 and $35,700, respectively.                                                                                                                                                 |
| EmploymentAgreements                                                      |  The Company’s principal officer, Mr. Desjourdy, is employed by the Company in his current positions at $18,000 per month on a month-to-month basis.  For the years ended December 31, 2010 and 2009, the aggregate amount paid to the Company’s principal officers was $216,000 and $226,000, respectively.  |

|  Accrued Officer Salary as of December 31, 2009   |                                                                                                                                                                                          |
|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Beginning balance                                                |                    $             - |
| Management salaries                                              |                        226,000                                             |
| Amount paid                                                      |                       (118,000)                                                 |
| Ending balance                                                   |                    $  108,000                                                        |

|  Accrued Officer Salary as of December 31, 2010  |                                                                                                                                               |
|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Beginning balance                                          |                    $  108,000             |
| Management salaries                                        |                        216,000  |
| Amount paid                                                |                        (54,000) |
| Ending balance                                             |                    $  270,000             |

| ConsultingAgreements                                                                     | The Company has entered into various scientific advisory and consulting agreements to support its development activities.  These agreements generally expire over several future years.  Amounts charged to operations in connection with these agreements for the years ended December 31, 2010 and 2009 amounted to approximately $53,000 and $53,000, respectively.  |
|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Finder’s Fees                                                                      | The Company has entered into agreements to pay finders’ fees for agreements entered into with certain companies for investment or revenue purposes.  The finders’ fees are based on a percentage of the investment or revenue.  No amounts were paid or accrued pursuant to any of these agreements during 2010 or 2009.                                         |
| 10.         Related PartyTransactions  | A member of the Board of Directors provides legal services to the Company.  Amounts paid for legal services rendered by the director, either individually or through his firm, totaled $6,734 and $9,638 for the years ended December 31, 2010 and 2009, respectively.                                                                                                  |
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                  |

----

| 10.         Related PartyTransactions(Continued)  | A member of the Board of Directors provides investor and public relations services to the Company.  Amounts paid for investor and public services rendered by the director, either individually or through her firm, totaled $22,684 and $10,000 for the years ended December 31, 2010 and 2009, respectively. The Company exchanges office space for services with a company owned by a relative of one of the Company’s officers and directors.  The officer and director is also a director in the other company.  The estimated annual value for 2010 and 2009 of the relationship is none and $6,400, respectively. On December 8, 2008 the Company signed a sale/license agreement with BioCide Pharma, Inc. covering upper respiratory tract products based on the Company’s proprietary iodine-based technology.  Under the agreement, the Company transferred ownership of its patent application covering use of its technology in the upper respiratory tract and granted an exclusive license to its other iodine-based technology for use in the field.  As partial consideration under the agreement, the Company received 625,000 shares of common stock in BioCide which represents 50% ownership of the company. Additionally, BioCide agreed to assume all of the Company’s outstanding patent fees and expenses (approximately $18,000) related to the patent application.  Under the agreement, BioCide was required to raise an aggregate of $1,250,000 in third party funding by the end of 2010.  BioCide has not to date raised any funding, and the Company now has the right to receive the technology sold/licensed back from Biocide.  So long as the Company retains at least a 10% ownership position in BioCide, it has the right to appoint one member of BioCide’s board of directors.  Two members of the Company’s Board of Directors own the remaining outstanding equity of BioCide, and are also officers and directors of BioCide.  As part of the transaction, one of the directors loaned BioCide $50,000 in order for BioCide to cover currently due patent prosecution expenses related to the transferred patent application.  |
|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11.         SubsequentEvents                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Private PlacementOf Securities                                                                      | On February 16, 2011, the Company sold in a private placement to an accredited investor an aggregate of 1,000,000 shares of Class A common stock for net proceeds of $30,000 in cash. The Company evaluated all events or transactions that occurred after December 31, 2010 through the date of this Annual Report.  The Company determined that it did not have any other subsequent events through April 15, 2011, which is the date the financial statements were issued, requiring recording or disclosure in the financial statements for the year ended December 31, 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

----

|   | Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
|--------|---------------------------------------------------------------------------------------------------------|

----

|   | Item 10.  Directors, Executive Officers and Corporate Governance |
|--------|----------------------------------------------------------------------------|

|   | Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|--------|--------------------------------------------------------------------------------------------------------------------|

----

|   | 2 | Form of Stock Option Agreement to be entered into between the Company and each option holder. |
|--------|---|-----------------------------------------------------------------------------------------------|

| Signature              | Title                               |        Date |
|------------------------|-------------------------------------|------------------------------------------------|
|                   |                                |                                           |
| /s/ Paul C. Desjourdy  | President, Chief Executive Officer, | April 15, 2011                                 |
| Paul C. Desjourdy      | Treasurer, Chief Financial Officer, |                                           |
|                   | General Counsel, and Director       |                                           |
|                   | (Principal Executive, Financial     |                                           |
|                   | and Accounting Officer)             |                                           |
|                   |                                |                                           |
| /s/ Jack H. Kessler    | Chairman of the Board of Directors  | April 15, 2011                                 |
| Jack H. Kessler        | and Secretary                       |                                           |
|                   |                                |                                           |
| /s/ James C. Richards  | Director                            | April 15, 2011                                 |
| James C. Richards      |                                |                                           |
|                   |                                |                                           |
| /s/ Richard F. Maradie | Director                            | April 15, 2011                                 |
| Richard F. Maradie     |                                |                                           |
|                   |                                |                                           |
| /s/ Eugene Lieberstein | Director                            | April 15, 2011                                 |
| Eugene Lieberstein     |                                |                                           |
|                   |                                |                                           |
| /s/ Yongjun Duan       | Director                            | April 15, 2011                                 |
| Yongjun Duan           |                                |                                           |
|                   |                                |                                           |
| /s/ Timothy Kane       | Director                            | April 15, 2011                                 |
| Timothy Kane           |                                |                                           |
|                   |                                |                                           |
| /s/ Kelly Black-White  | Director                            | April 15, 2011                                 |
| Kelly Black White      |                                |                                           |

----

| 3.1 | Amended Certificate of Incorporation of the Company. (previously filed as exhibit 3.1 to Form 10-KSB for the year ended December 31, 2005 and incorporated by reference) |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | Amended By-Laws of the Company. (previously filed as exhibit 3.2 to Form 10-QSB for the quarter ended June 30, 1999 and incorporated by reference) |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3 | Agreement of Merger, dated as of August 4, 1993, between the Company and Symbollon Corporation, a Massachusetts corporation (including Certificate of Merger and other state filings). (previously filed as exhibit number 3.3 of the Registration Statement (the “Registration Statement”) on Form SB-2 (Registration No. 33-68828) filed on November 24, 1993 and declared effective on December 7, 1993, and incorporated by reference) |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1 | Form of Specimen Class A Common Stock Certificate. (previously filed as exhibit number 4.2 of the Registration Statement and incorporated by reference) |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1 | 1993 Stock Option Plan of the Company, as amended. (incorporated by reference to Exhibit C to the Company’s 2005 Annual  Stockholders Meeting Proxy Statement filed under cover of Schedule 14A dated May 4, 2005) |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | Form of Indemnification Agreement between the Company and each officer and director of the Company. (previously filed as exhibit number 10.6 of the Registration Statement and incorporated by reference) |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | Form of Stock Option Agreement to be entered into between the Company and each option holder. (previously filed as exhibit number 10.10 to Form 10-KSB for the year ended December 31, 1993 and incorporated by reference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | 2006 Non-Employee Directors’ Stock Option Plan of the Company. (previously filed as exhibit number 10.1 to Form 8-K filed on May 30, 2006 and incorporated by reference) |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.5 | 1995 Non-Employee Directors’ Stock Option Plan of the Company. (previously filed as exhibit number 10.1 to Form 10-QSB for the quarter ended June 30, 1995 and incorporated by reference) |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.6 | Form of Warrant for the purchase of shares of Class A Common Stock, dated as of February 28, 2006, issued to certain purchasers of the Company’s securities (previously filed as exhibit number 10.1 to Form 8-K filed on March 7, 2006 and incorporated by reference) |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.7 | Securities Purchase Agreement, dated as of June 2, 2006, between Symbollon and certain purchasers of Symbollon’s securities. (previously filed as exhibit number 10.1 to Form 8-K filed on June 7, 2006 and incorporated by reference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.8 | Form of Redeemable Warrant expiring on June and August 2011 for the purchase of shares of Class A common stock issued to certain purchasers of Symbollon’s securities. (previously filed as exhibit number 10.2 to Form 8-K filed on June 7, 2006 and incorporated by reference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.9 | Registration Rights Agreement, dated as of June 2, 2006, between Symbollon and certain purchasers of Symbollon’s securities. (previously filed as exhibit number 10.3 to Form 8-K filed on June 7, 2006 and incorporated by reference) |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.10 | Form of Redeemable Warrant expiring December 2011 for the purchase of shares of Class A common stock issued to certain purchasers of Symbollon’s securities. (previously filed as exhibit number 10.22 to the Registration Statement on Form SB-2 (Registration No. 333-140200) filed on January 25, 2007 (the “2007 Registration Statement”) and declared effective on February 7, 2007, and incorporated by reference) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.11 | Form of Subscription Agreement, dated as of December 29, 2006, between Symbollon and certain purchasers of Symbollon’s securities. (previously filed as exhibit number 10.23 to the 2007 Registration Statement) |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.12 | Securities Purchase Agreement, dated as of September 27, 2007, between Symbollon and certain purchasers of Symbollon’s securities (previously filed as exhibit number 10.1 to Form 10-QSB for the quarter ended September 30, 2007 and incorporated by reference) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.13 | Form of Subscription Agreement, dated as of September 27, 2007, between Symbollon and certain purchasers of Symbollon’s securities (previously filed as exhibit number 10.2 to Form 10-QSB for the quarter ended September 30, 2007 and incorporated by reference) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.14 | Form of Redeemable Warrant expiring on September 2012 for the purchase of shares of Class A common stock issued to certain purchasers of Symbollon’s securities (previously filed as exhibit number 10.3 to Form 10-QSB for the quarter ended September 30, 2007 and incorporated by reference) |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.15 | Registration Rights Agreement, dated as of September 27 2007, between Symbollon and certain purchasers of Symbollon’s securities (previously filed as exhibit number 10.4 to Form 10-QSB for the quarter ended September 30, 2007 and incorporated by reference) |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.16 | Stock Purchase Agreement, dated as of October 8, 2010, between Symbollon and Organic Business Alliances, LLC (previously filed as exhibit number 10.1 to Form 8-K filed on October 12, 2010 and incorporated by reference) |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.17 | Technology License Agreement, dated as of October 8, 2010, between Symbollon and Organic Business Alliances, LLC (previously filed as exhibit number 10.2 to Form 8-K filed on October 12, 2010 and incorporated by reference) |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 31.1 | Certification of the Chief Executive Officer and Chief Financial Officer required by Securities Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 32.1 | Certification of the Chief Executive Officer and Chief Financial Officer required by Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. * |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| * | Filed herewith. |
|---|-----------------|

----